Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Aberrant signaling through the Axl receptor tyrosine kinase has been associated with a myriad of human diseases, most notably metastatic cancer, identifying Axl and its ligand Gas6 as important therapeutic targets. Using rational and combinatorial approaches, we engineered an Axl 'decoy receptor' that binds Gas6 with high affinity and inhibits its function, offering an alternative approach from drug discovery efforts that directly target Axl. Four mutations within this high-affinity Axl variant caused structural alterations in side chains across the Gas6-Axl binding interface, stabilizing a conformational change on Gas6. When reformatted as an Fc fusion, the engineered decoy receptor bound Gas6 with femtomolar affinity, an 80-fold improvement compared to binding of the wild-type Axl receptor, allowing effective sequestration of Gas6 and specific abrogation of Axl signaling. Moreover, increased Gas6 binding affinity was critical and correlative with the ability of decoy receptors to potently inhibit metastasis and disease progression in vivo.

Original publication

DOI

10.1038/nchembio.1636

Type

Journal article

Journal

Nat Chem Biol

Publication Date

11/2014

Volume

10

Pages

977 - 983

Keywords

Animals, Binding Sites, Disease Progression, Dose-Response Relationship, Drug, Genetic Engineering, Humans, Immunoglobulin Fc Fragments, Intercellular Signaling Peptides and Proteins, Mice, Models, Molecular, Mutation, Neoplasm Metastasis, Neoplasms, Experimental, Protein Binding, Proto-Oncogene Proteins, Receptor Protein-Tyrosine Kinases, Recombinant Fusion Proteins, Signal Transduction, Structure-Activity Relationship